Cell子刊：抗抑郁药竟是抗癌利器？我国学者发现，帕罗西汀可诱导癌细胞焦亡，增强免疫疗法

Core Viewpoint - The research indicates that Paroxetine, a commonly used antidepressant, shows significant efficacy against malignant melanoma, particularly in cases with BRAF V600E mutations that are resistant to targeted therapies [3][5]. Group 1: Research Findings - A study published in Cell Reports Medicine reveals that Paroxetine induces pyroptosis in melanoma cells, a unique mechanism of cell death distinct from traditional apoptosis [3][7]. - The mechanism involves blocking serotonin reuptake, leading to reduced intracellular serotonin levels, which affects DNA repair gene expression and ultimately results in DNA damage accumulation and endoplasmic reticulum stress [7][9]. - Paroxetine is effective against BRAFi/MEKi resistant melanoma due to lower expression of TPH1, making these cells more sensitive to treatment [11]. Group 2: Clinical Implications - The findings suggest multiple clinical benefits: Paroxetine is an already approved drug with known safety, allowing for quicker clinical application [14]. - It serves dual purposes as both an antidepressant and an anti-cancer agent, making it particularly suitable for advanced cancer patients [14]. - The drug offers new options for patients with resistance to targeted therapies and enhances the effectiveness of immune therapies by transforming "cold tumors" into "hot tumors" [11][14].